Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues

Author： Roberts J Scott   Dunn Laura B   Rabinovici Gil D  

Publisher： Future Medicine

ISSN： 1758-2024

Source： Neurodegenerative Disease Management, Vol.3, Iss.3, 2013-06, pp. : 219-229

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cerebral amyloid PET imaging in Alzheimer’s disease

By Jack Clifford   Barrio Jorge   Kepe Vladimir  

Acta Neuropathologica, Vol. 126, Iss. 5, 2013-11 ,pp. : 643-657

Springer Publishing Company

Access to resources Recommend Favorite

Practical Issues in Stem Cell Therapy for Alzheimer's Disease

By  

Current Alzheimer Research, Vol. 4, Iss. 4, 2007-09 ,pp. : 370-377

Bentham Science Publishers

Access to resources Recommend Favorite

Development of a PET/SPECT agent for amyloid imaging in Alzheimer’s disease

By Wang Yanming   Klunk William   Debnath Manik   Huang Guo-Feng   Holt Daniel   Shao Li   Mathis Chester  

Journal of Molecular Neuroscience, Vol. 24, Iss. 1, 2004-02 ,pp. : 55-62

Humana Press, Inc

Access to resources Recommend Favorite

Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease

By  

Current Alzheimer Research, Vol. 12, Iss. 6, 2015-01 ,pp. : 563-571

Bentham Science Publishers

Access to resources Recommend Favorite

Amyloid Beta Protein as a Marker or Risk Factor of Alzheimer's Disease

By  

Current Alzheimer Research, Vol. 4, Iss. 4, 2007-01 ,pp. : 359-363

Bentham Science Publishers

Access to resources Recommend Favorite